Can I read SUO 2025 Topline Results From BOND-003 Cohort P Podium on EtoBox?

SUO 2025 Topline Results From BOND-003 Cohort P Podium by allanyoyo is a document available to read on EtoBox.

What is SUO 2025 Topline Results From BOND-003 Cohort P Podium about?

The BOND-003 study evaluated the efficacy and safety of Cretostimogene Grenadenorepvec in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Results showed a strong high-grade event-free survival (HG-EFS) rate of 92.8% at 3 months and a well-tolerated safety profile with no grade 3 treatment-related adverse events. The findings support the ongoing submission for FDA approval for this treatment in the specified patient population.

Author

allanyoyo

Language

EN